DOWNSTREAM PROCESSING FEATURED ARTICLES
3 Critical Considerations For Cell Therapy Manufacturing
While autologous cell therapies offer promise in the way of patient treatment, manufacturing them is a complex process requiring thorough understanding of the cell type(s) that a company will be providing as therapy. When it comes to ensuring the successful manufacturing of a cell therapy drug, Ross Tubo, chief scientific officer at Vericel Corporation, says there are three critical areas where particular attention should be paid.
-
Boehringer Ingelheim Implements Flexible Fully Disposable Up- And Downstream Manufacturing For Biopharmaceuticals
Boehringer Ingelheim has developed and now implemented a flexible set-up and operational approach for disposable technologies within its global biopharmaceutical development and manufacturing network.
-
Battelle Develops Transgenic Plant Protein Production Platform If your company is looking for plant-based protein sources, look into a new transgenic tobacco from Battelle’s Pacific Northwest Laboratory...
-
Horizon Discovery And Boehringer Ingelheim Enter Oncology Research Service Collaboration
Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, recently announced it has signed a research service collaboration agreement with Boehringer Ingelheim.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Turning Data Into Information
As biopharmaceutical manufacturing has evolved from small-scale lab production in small flasks to massive commercial production in deep-tank bioreactors, an avalanche of production data has evolved to support it. From individual unit operation skids to distributed control systems and enterprise resource planning tools, biomanufacturing today is buried by the sheer quantity of data coming in from the manufacturing floor.
-
![Monoclonal Antibody Purification Platform Using High-Capacity Protein A And Mixed-Mode Chromatography]( "Monoclonal Antibody Purification Platform Using High-Capacity Protein A And Mixed-Mode Chromatography")
Monoclonal Antibody Purification Platform Using High-Capacity Protein A And Mixed-Mode ChromatographyThe first step in purification of an important class of therapeutic proteins, the polyclonal or monoclonal antibodies (mAbs), is their capture from plasma or tissue culture supernatants. Protein A–based media are by far the most common class of affinity products used for this purpose.
-
Important Considerations For Implementing A Single-Use Biomanufacturing Strategy
Recent trends in biomanufacturing technology and the biopharmaceutical market are supporting the increased adoption of single-use (SU) manufacturing systems. On the demand-side, the biopharma industry is focusing on niche and rare diseases with smaller patient populations, resulting in the need for smaller, more agile biomanufacturing capacity. By Jodi M. Zobrist and Nicole W. O'Brien, Ph. D., Gallus Biopharmaceuticals, LLC
-
Efficiencies Of Natural Convection In Passive Pallet Shippers
Bulk transportation of temperature sensitive pharmaceuticals and biologics has become a common practice due to complex global supply chains. By Iftekhar Ahmed, Ben VanderPlas, and Stu Krupnick
-
Proven Long Life Lasers™ In Optical Particle Counters Optical particle counters (OPC) utilize light illumination and extinction to determine the presence, size, number and/or concentration of particles. Particles are typically suspended in a fluid or air, which flow through the volume that is illuminated and viewed by the detection system.
-
Managing Cell-Based Potency Assays: From Development To Lifecycle Maintenance
Characterization of a biological product — which includes the determination of physicochemical properties, biological activity, immunochemical properties, purity and impurities — is necessary to establish the safety and efficacy profile of a given product (ICH Q6B). By Dr. Weihong Wang, manager, Molecular and Cell Biology, Eurofins Lancaster Laboratories
DOWNSTREAM PROCESSING PRODUCTS
Time-to-clinic and time-to-market are two key factors in successful biopharmaceutical development.
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.